Viking Therapeutics, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $26.88
- 52-Week Range
- $23.82 – $43.10
- Market Cap
- $3.34B
- P/E (TTM)
- —
- EPS (TTM)
- -5.42
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 5.67
- PEG Ratio
- —
- Return on Equity
- -96.37%
- Return on Assets
- -47.23%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 7.27
- Debt/Equity
- 0.43
- Total Debt
- $254.69M
- Free Cash Flow
- $-237.78M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $2.63B
Market Snapshot
About
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. The company's pipeline includes drug candidates for non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, and other metabolic conditions. Viking focuses on small molecule therapeutics targeting nuclear receptors.